Drug intelligence / Profile preview

Cartivelle

Development stage: Unknown
Lead developer: Regrow Biosciences
Modality: Cell Therapies
Administration: Intraarticular

Overview

Cartivelle is an autologous cell therapy developed by Regrow Biosciences for the treatment of articular cartilage injuries. The therapy involves harvesting a small biopsy of healthy cartilage from the patient, isolating the chondrocytes, and expanding them in a specialized laboratory. These cultured chondrocytes are then re-implanted into the patient's damaged joint to facilitate the regeneration of hyaline-like cartilage. Cartivelle is approved for market commercialization in India and is designed to restore joint function and alleviate pain in patients with cartilage defects.

Brand names: CartivelleCartigrow
Other names: autologous cultured chondrocytesautologous adult live cultured chondrocytes

Beyond the preview

Go deeper on Cartivelle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cartivelle.

Explore the full profile